CA 074 (Synonyms: CA-074,CA074) |
|
カタログ番号GC16317
|
CA 074はKi値が2-5nMのカテプシン Bの選択的阻害剤である。CA 074は精製のラットのカテプシン Bに対して、カテプシンHおよびLよりも10000-30000倍強力である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 134448-10-5
Sample solution is provided at 25 µL, 10mM.
CA 074はKi値が2-5nMのカテプシン Bの選択的阻害剤である。CA 074は精製のラットのカテプシン Bに対して、カテプシンHおよびLよりも10000-30000倍強力である。CA 074はほとんどのリソソームシステインプロカスパーゼを不可逆的に阻害する天然のペプチジルエポキシドであるE-64の合成アナログである。CA 074は細胞膜を通過できないが、そのメチルエステル型のCA-074 Me(GC15917)は細胞膜を通過できる。
In vitroでは、HT29、DLD1およびSW480細胞にCA-074(10μM)を2-3週間処理すると、マトリゲルを介した細胞浸潤が約45-60%著しく阻害された。
In vivoでは、ヒトメラノーマ細胞を接種したCA 074(10mg/kg)を静脈に投与し、腫瘍成長および肺転移数が大幅に抑制された。CA 074(50mg/kg)を4T1.2腫瘍保有マウスに腹腔内に投与し、腫瘍成長が大幅に抑制され、腫瘍のカテプシン B活性が低下し、肺転移および骨転移が阻害された。局所的脳虚血のあるラットにCA 074(4 mg/kg)を静脈に投与し、カテプシン BおよびLの濃度が大幅に低下し、脳組織の好酸球性(壊死性)およびアポトーシス性神経細胞数が増えた。
References:
[1] Towatari T, Nikawa T, Murata M, et al. Novel epoxysuccinyl peptides A selective inhibitor of cathepsin B, in vivo[J]. FEBS letters, 1991, 280(2): 311-315.
[2] Matsumoto K, Mizoue K, Kitamura K, et al. Structural basis of inhibition of cysteine proteases by E‐64 and its derivatives[J]. Peptide Science, 1999, 51(1): 99-107.
[3] Patel N, Nizami S, Song L, et al. CA‐074Me compound inhibits osteoclastogenesis via suppression of the NFATc1 and c‐FOS signaling pathways[J]. Journal of Orthopaedic Research, 2015, 33(10): 1474-1486.
[4] Bian B, Mongrain S, Cagnol S, et al. Cathepsin B promotes colorectal tumorigenesis, cell invasion, and metastasis[J]. Molecular carcinogenesis, 2016, 55(5): 671-687.
[5] Matarrese P, Ascione B, Ciarlo L, et al. Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study[J]. Molecular cancer, 2010, 9: 1-14.
[6] Withana N P, Blum G, Sameni M, et al. Cathepsin B inhibition limits bone metastasis in breast cancer[J]. Cancer research, 2012, 72(5): 1199-1209.
[7] Özkara E, Durmaz R, Özbek Z, et al. The Effect of Ca-074 (Cathepsın B Inhibitor) on Necrotic and Apoptotic Neuronal Cell Death in Model of Cerebral Ischemia[J]. Osmangazi Tıp Dergisi, 2023, 45(5): 781-790.
| 細胞実験[1]: | |
細胞株 | HT29、DLD1およびSW480細胞株 |
準備方法 | HT29、DLD1およびSW480細胞は、10 μMのCA 074の有無にかかわらず、ソフトアガロースの中で2-3週間培養された。 |
反応条件 | 10μM; 2–3週間 |
アプリケーション | CA 074はマトリゲルを介した細胞浸潤を約45-60%著しく阻害された。 |
| 動物実験 [2]: | |
動物モデル | CD-1雄ヌード(nu/nu)マウス |
準備方法 | MM4細胞をマウスの後肢の筋に投与した。腫瘍移植あと6日目(腫瘍量約250mg)から、マウスにCA 074を10 mg/kgで8日間連続静脈に投与した。 |
投与形態 | 10mg/kg; i.v. |
アプリケーション | CA 074は腫瘍成長を大幅に抑制し、人工肺における転移の数を抑制した。 |
References: | |
| Cas No. | 134448-10-5 | SDF | |
| 同義語 | CA-074,CA074 | ||
| Chemical Name | (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid | ||
| Canonical SMILES | CCCNC(=O)C1C(O1)C(=O)NC(C(C)CC)C(=O)N2CCCC2C(=O)O | ||
| Formula | C18H29N3O6 | M.Wt | 383.44 |
| 溶解度 | ≥ 19.17mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.608 mL | 13.0398 mL | 26.0797 mL |
| 5 mM | 521.6 μL | 2.608 mL | 5.2159 mL |
| 10 mM | 260.8 μL | 1.304 mL | 2.608 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)